Skip to main content

Our funding in numbers.

The Boehringer Ingelheim Foundation fulfils its statutory purpose by funding excellent basic research in medicine, biology, chemistry, and pharmacy. Its funding focus lies on the University of Mainz.

The Foundation’s Germany-wide Plus 3 and Exploration Grants programmes offer outstanding and independent junior group leaders the freedom necessary to realise their scientific potential and to test new ideas. The Foundation also supports scientific conferences around the world, with the particular aim of promoting dialogue between different generations of scientists.

The Foundation awards the internationally renowned Heinrich Wieland Prize to honour distinguished scientists from around the world for their ground-breaking research.It also endows awards for excellent junior researchers, namely the Boehringer Ingelheim Prize and four PhD student prizes at the University of Mainz.

As a recognised charitable organisation, the Boehringer Ingelheim Foundation is not subject to corporate and trade taxes (current notice of tax exemption issued by the Bingen-Alzey tax office on 12 December 2022, for 2018 to 2020, tax ID number 08/667/10470). The annual financial statement of the Boehringer Ingelheim Foundation is audited by Rödl & Partner GmbH Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft based on the Generally Accepted Standards for the Review of Financial Statements (IDW AuS 900).

Expenditures of the Boehringer Ingelheim Foundation in 2020

In 2020, the Boehringer Ingelheim Foundation spent some 21.3 million euros on the promotion of science. Its administration costs amounted to about 484,000 euros. In this fiscal year there was a one-off special item from the transfer of pension obligations, which was deducted from the administrative costs.

Funds approved in 2020

In 2020, the Boehringer Ingelheim Foundation approved approximately 7.3 million euros in funding. These newly approved grants were applied to the Plus 3 and Exploration Grants programmes, for scientific conferences, and scientific awards, as well as newly approved institutional fundings, such as the Leibniz Institute for Resilience Research (LIR) in Mainz. Due to the COVID-19-pandemic the approved amount for scientific conferences was much smaller than in previous years.

In addition, in 2020, the Foundation paid out grants for initiatives and projects decided upon in previous years. Among the beneficiaries of these grants were the Institute of Molecular Biology (IMB), the Faculty of Biology at the University of Mainz, the International PhD Programme (IPP) in Mainz, a cardiovascular research consortium and the German Resilience Center (DRZ, now Leibniz Institute for Resilience Research (LIR)) at the Mainz University Medical Center, and various projects within the Plus 3 and Exploration Grants programmes. The BIS also funded the EMBL in Heidelberg and the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine (BIF).